These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 3286265)
41. [Anti-arrhythmia treatment (clinical problems, classification of anti-arrhythmia drugs and personal experience]. Walczak F Kardiol Pol; 1992; 36(2):97-104. PubMed ID: 1583833 [No Abstract] [Full Text] [Related]
42. [Mechanism of action of antiarrhythmic agents]. Méndez R Arch Inst Cardiol Mex; 1977; 47(2):223-32. PubMed ID: 901057 [No Abstract] [Full Text] [Related]
43. Use-dependent modulation of myocardial conduction by a new class of HERG agonists: deal breaker or cherry on top? Akar FG J Cardiovasc Electrophysiol; 2010 Aug; 21(8):930-2. PubMed ID: 20367661 [No Abstract] [Full Text] [Related]
44. Ranolazine in Cardiac Arrhythmia. Saad M; Mahmoud A; Elgendy IY; Richard Conti C Clin Cardiol; 2016 Mar; 39(3):170-8. PubMed ID: 26459200 [TBL] [Abstract][Full Text] [Related]
45. Drug development for treatment of cardiac arrhythmias: targeting the gap junctions. Wit AL; Duffy HS Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H16-8. PubMed ID: 17890421 [No Abstract] [Full Text] [Related]
47. Pharmacotherapy of cardiac arrhythmias--basic science for clinicians. Shu J; Zhou J; Patel C; Yan GX Pacing Clin Electrophysiol; 2009 Nov; 32(11):1454-65. PubMed ID: 19744278 [TBL] [Abstract][Full Text] [Related]
48. Proceedings: Comparison of the effects of mexiletine, lignocaine and procainamide on canine Purkinje fibres. Allen JD; Arnold JM J Physiol; 1974 Jan; 236(1):26P-28P. PubMed ID: 4818502 [No Abstract] [Full Text] [Related]
49. Electrophysiologic and pharmacokinetic profile of the new antiarrhythmic drug TYB-3823 in humans. Crijns HJ; Oosterhuis B; Wiesfeld AC; De Bruin H; Mensink CK; Jonkman JH; Kozma C; Lie KI J Cardiovasc Pharmacol; 1993 Jan; 21(1):1-6. PubMed ID: 7678662 [TBL] [Abstract][Full Text] [Related]
50. Mechanism of action of antifibrillatory drugs. Heistracher P Naunyn Schmiedebergs Arch Pharmakol; 1971; 269(2):199-212. PubMed ID: 4254278 [No Abstract] [Full Text] [Related]
51. Experimental models of reentry, antiarrhythmic, and proarrhythmic actions of drugs. Complexities galore! el-Sherif N Circulation; 1991 Oct; 84(4):1871-5. PubMed ID: 1914122 [No Abstract] [Full Text] [Related]
52. Electrophysiological basis for antiarrhythmic drug action. Wit AL Clin Physiol Biochem; 1985; 3(2-3):127-34. PubMed ID: 3891195 [TBL] [Abstract][Full Text] [Related]
53. Adjusting the beat. Berry SL; Schleicher CA Am J Nurs; 1992 Jun; 92(6):28-32. PubMed ID: 1605277 [No Abstract] [Full Text] [Related]
54. New class III antiarrhythmic drugs. Katritsis D; Camm AJ Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759 [TBL] [Abstract][Full Text] [Related]
55. [Classification and mechanism of action of anti-arrhythmia drugs]. Gasic S Wien Med Wochenschr; 1994; 144(14-15):338-42. PubMed ID: 7825324 [TBL] [Abstract][Full Text] [Related]
56. [The working classification of antiarrhythmic drugs based on the pathogenetic approach to treatment of cardiac arrhythmias]. Lipnitskiĭ TN; Kozlovskiĭ VA Lik Sprava; 2002; (8):26-30. PubMed ID: 12669534 [TBL] [Abstract][Full Text] [Related]
57. [Electrophysiologic study of fenoxedil chlorhydrate]. Gerard R; Burlot J; Levy S; Balansard P; Jullien G; Ebagosti A Acta Cardiol; 1976; 31(5):385-99. PubMed ID: 1088046 [TBL] [Abstract][Full Text] [Related]